structural basis recognition synaptic vesicle protein 2c botulinum neurotoxin 
botulinum neurotoxin bont/a belongs dangerous class bioweapons despite bont/a used treat wide range common medical conditions migraines variety ocular motility movement disorders bont/a probably best known use antiwrinkle agent cosmetic applications including botox dysport bont/a application causes long-lasting flaccid paralysis muscles inhibiting release neurotransmitter acetylcholine cleaving synaptosomal-associated protein snap- within presynaptic nerve terminals two types bont/a receptor identified required bont/a toxicity therefore likely cooperate other: gangliosides members synaptic vesicle glycoprotein sv2 family putative transporter proteins predicted transmembrane domains associate receptor-binding domain toxin recently fibroblast growth factor receptor fgfr3 also reported potential bont/a receptor sv2 proteins bont/a-binding site mapped luminal domain molecular details interaction bont/a sv2 unknown determined high-resolution crystal structure bont/a receptor-binding domain bont/a-rbd complex sv2c luminal domain sv2c-ld sv2c-ld consists right-handed quadrilateral beta-helix associates bont/a-rbd mainly backbone-to-backbone interactions open beta-strand edges manner resembles inter-strand interactions amyloid structures competition experiments identified peptide inhibits formation complex findings provide strong platform development novel antitoxin agents rational design bont/a variants improved therapeutic properties 
